Level Laser Therapy

1. Completely devoid of side effects and trauma.
2. Its compact size allows for effortless portability, facilitating usage in diverse environments.
3. User-friendly operation makes it convenient to use.
4. Shell crafted from premium, exuding sophistication.plug-in-on
5. Operates independently without the need for a host device; direct power connection suffices.
6. Validated through active clinical trials and holds certifications from CFDA and CE, affirming its efficacy.

Our research utilizing transcranial photobiomodulation (tPBM) to improve cognition in chronic TBI using red/near-infrared (NIR) light-emitting diodes (LEDs) to deliver light to the head. tPBM improves mitochondrial function increasing oxygen consumption, production of adenosine triphosphate (ATP), and improving cellular energy stores. Nitric oxide is released from the cells increasing regional blood flow in the brain.

Ongoing studies: Ongoing, current studies involve TBI patients who have been treated with tLED using either 26 J/cm2 per LED location on the head or treated with intranasal only (iLED) using red NIR (810 nm) diodes placed into the nostrils. The NIR iLED is hypothesized to deliver photons to the hippocampus, and the red 633 nm iLED is believed to increase melatonin. Results have been similar to the previously published tLED study.

One of the most thoroughly studied applications of photobiomodulation (PBM) in animal models is its potential use as a therapy for acute stroke. Human clinical trials have shown that PBM can significantly enhance recovery outcomes in stroke patients.



In the initial clinical trial, PBM was administered within 24 hours of a stroke event, and significant improvements were observed when the treatment was given 18 hours post-stroke. This was applied across the entire head, irrespective of stroke type. A single laser treatment was used, and results were noticeable five days later. At the 90-day mark, 70% of the patients who received low-level laser therapy (LLLT) continued to show significant improvement.



A second clinical trial found that LLLT was effective for treating moderate to severe strokes, though not severe ones. The third trial did not yield any significant results. Some evidence suggests that the timing between stroke occurrence and PBM treatment initiation may be a critical factor.



Numerous studies have demonstrated PBM's effectiveness in aiding brain injury recovery. Experiments with mice revealed that those treated with LLLT experienced significantly reduced neurological deficits, including less cortical tissue loss, improved mobility, reduced depression and anxiety, higher levels of brain-derived neurotrophic factor (BDNF), and better learning and memory.



In a small study involving humans with traumatic brain injuries (TBIs) ranging from 10 months to 8 years old, the use of red and near-infrared light-emitting diodes (LEDs) three times a week for 10 minutes over a six-week period resulted in significant improvements in executive function, verbal learning, free recall, sleep, and reduced PTSD symptoms.